Drug developers will now have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Akagera Medicines, a Rwandan biotech company has announced promising results after completing early stages of preclinical ...

Quantoom Biosciences and DIANT Pharma Inc. Collaborate to Enhance mRNA Supply Chain Efficiency Quantoom Biosciences and DIANT Pharma Inc. are proud to announce a strategic collaboration to advance the ...

The "RNA Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Global RNA Analysis Market was ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...

Customers looking for an mRNA therapeutic partner should prioritize operational excellence and choose flexible CDMOs.

Never before had so much money and effort been jointly invested to develop vaccines. The speed with which mRNA immunisations ...

They plan to expand the scope of properties that can be predicted and add processing methods, which can be quite influential, to the model. They also hope to expand the model to include other ...

A common interest in language unites social scientists and natural language processing (NLP) researchers. While both fields leverage the strong connection between language and behavior ...

Yet vaccines using the new technology of mRNA were developed by Moderna and Pfizer/BioNTech in a matter of months, and were already being put into arms by the first anniversary of the pandemic.